- Home
- FLO vs VKTX Comparison
FLO vs VKTX Comparison
Compare FLO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLO
- VKTX
- Stock Information
- Founded
- FLO 1919
- VKTX 2012
- Country
- FLO United States
- VKTX United States
- Employees
- FLO N/A
- VKTX N/A
- Industry
- FLO Packaged Foods
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FLO Consumer Staples
- VKTX Health Care
- Exchange
- FLO Nasdaq
- VKTX Nasdaq
- Market Cap
- FLO 4.9B
- VKTX 5.6B
- IPO Year
- FLO N/A
- VKTX 2015
- Fundamental
- Price
- FLO $23.46
- VKTX $54.13
- Analyst Decision
- FLO Hold
- VKTX Strong Buy
- Analyst Count
- FLO 3
- VKTX 9
- Target Price
- FLO $23.67
- VKTX $111.78
- AVG Volume (30 Days)
- FLO 1.1M
- VKTX 3.2M
- Earning Date
- FLO 08-16-2024
- VKTX 10-23-2024
- Dividend Yield
- FLO 4.10%
- VKTX N/A
- EPS Growth
- FLO N/A
- VKTX N/A
- EPS
- FLO 0.61
- VKTX N/A
- Revenue
- FLO $5,130,088,000.00
- VKTX N/A
- Revenue This Year
- FLO $1.91
- VKTX N/A
- Revenue Next Year
- FLO $1.72
- VKTX N/A
- P/E Ratio
- FLO $38.57
- VKTX N/A
- Revenue Growth
- FLO 2.53
- VKTX N/A
- 52 Week Low
- FLO $19.64
- VKTX $8.28
- 52 Week High
- FLO $26.12
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- FLO 59.36
- VKTX 40.88
- Support Level
- FLO $22.69
- VKTX $58.90
- Resistance Level
- FLO $23.84
- VKTX $64.91
- Average True Range (ATR)
- FLO 0.35
- VKTX 4.78
- MACD
- FLO 0.05
- VKTX -1.12
- Stochastic Oscillator
- FLO 68.44
- VKTX 13.29
About FLO Flowers Foods Inc.
Flowers Foods Inc is an American company producing bakery food for retail and foodservice across the United States. The product portfolio includes fresh breads, buns, rolls, snack cakes, and tortillas. The company distributes to supermarkets, convenience stores, and restaurants. The key brands are Nature's Own, Whitewheat, Cobblestone Bread, Wonder, Dave's Killer Bread, Canyon Bakehouse, Mrs. Freshley's, and Tastykake.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.